Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Paroxetine hydrochloride (Paroxetine HCl) is a serotonin uptake inhibitor that is effective in the treatment of depression.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 45.00 | |
50 mg | In stock | $ 54.00 | |
100 mg | In stock | $ 78.00 | |
200 mg | In stock | $ 112.00 | |
500 mg | In stock | $ 153.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 50.00 |
Description | Paroxetine hydrochloride (Paroxetine HCl) is a serotonin uptake inhibitor that is effective in the treatment of depression. |
Targets&IC50 | GRK2:14 μM |
In vitro | Paroxetine, at an ED50 of 1-3 mg/kg when administered orally (PO), demonstrates the capability to prevent the depletion of serotonin (5-HT) in rats' brains induced by p-chloroamphetamine (PCA), signifying an inhibition of serotonin uptake in vivo. Additionally, in isolated rat hypothalamic synaptosomes, paroxetine exhibits a dose-dependent inhibition of [3H] - 5-HT uptake with an ED50 of 1.9 mg/kg, while showing minimal effects on the uptake of [3H] - norepinephrine (NA), with an ED50 exceeding 30 mg/kg. |
In vivo | Paroxetine, a highly effective hydroxylated metabolite inhibitor of (dextromethorphan), demonstrates the concentration-dependent reduction in the firing rate of serotonergic neurons within the DRN of super fused brainstem slices at 1-300 μM, with an IC50 value of 1.4 μM. With an inhibition constant (Ki) of 2 mM, Paroxetine's inhibitory capacity surpasses that of fluoxetine or norfluoxetine, indicating its more potent effect. Moreover, in rat cortical and in vitro hypothalamic synapses, Paroxetine acts as a potent and specific inhibitor of [3H]-5-hydroxytryptamine (5-HT), with a Ki of 1.1 nM. Its antidepressant activity is attributed to the increased concentration of 5-HT in the extracellular compartment, thereby enhancing serotonergic neurotransmission. Paroxetine also inactivates CYP2D6 by forming metabolic intermediate complexes. |
Cell Research | Paroxetine is dissolved in DMSO. Cell viability is determined by the tetrazolium salt 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. BV2 and primary microglial cells are initially seeded into 96-well plates at a density of 1×104 cells/well and 5×104 cells/well, respectively. Following treatment, MTT (5 mg/mL in PBS) is added to each well and incubated at 37°C for four hours. The resulting formazan crystals are dissolved in dimethylsulfoxide (DMSO). The optical density is measured at 570 nm, and results are expressed as a percentage of surviving cells compared with the control. |
Synonyms | Paroxetine HCl, BRL29060 hydrochloride, FG-7051, BRL29060A |
Molecular Weight | 365.826 |
Formula | C19H21ClFNO3 |
CAS No. | 78246-49-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 10 mg/mL (27.33 mM)
Ethanol: 35 mg/mL (95.67 mM)
DMSO: 73 mg/mL (199.54 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Paroxetine hydrochloride 78246-49-8 Autophagy GPCR/G Protein Neuroscience GRK 5-HT Receptor Serotonin Transporter AChR BRL 29060 Hydrochloride Paroxetine Hydrochloride BRL 29060 FG7051 Paroxetine HCl inhibit Paroxetine BRL29060 Hydrochloride SLC6A4 BRL-29060 Hydrochloride BRL29060 FG 7051 Inhibitor SERT BRL29060 hydrochloride BRL-29060 5-HTT FG-7051 BRL29060A inhibitor